Test Now Incorporates Enhanced Machine Learning Risk Prediction Algorithm Plans Underway to Commercialise Testing Service Through Trinity ...
Mdxhealth Highlights Data from Oxford's ProMPT Study Demonstrating the Genomic Prostate Score GPS Test Predicts Adverse Outcomes Across Multiple Treatment Settings at EAU 2026 IRVINE, California - Mar ...
Test Now Incorporates Enhanced Machine Learning Risk Prediction Algorithm Plans Underway to Commercialise Testing Service Through Trinity Biotech's New York Reference Laboratory DUBLIN and NEW YORK, ...
HKSH Medical Group (HKSH) today announced the results of Asia's first clinical study on early-stage prostate cancer patients receiving five-session of proton therapy.* The results show significant ...
In this article, we will look at the 10 best diagnostics and research stocks to buy according to analysts. The diagnostics ...
Cop always on work. Space elves have an intern! Rampant laziness and total ignorance. Bad pulley bearing without proper identification. Catsup chips and cut fish at once! Ninth the outward leg. Tea ...
Prostate Biopsy Findings. PROSTATE biopsy under local anesthesia showed similar safety and detection outcomes, with better ...
The GPS Mdx test is a 17-gene expression assay performed on prostate biopsy tissue that may identify signals of favorable vs unfavorable pathology.
An ultrasound-based treatment for prostate cancer showed better safety and operative metrics versus robotic radical ...
Comprehensive, up-front full-panel NGS across lung cancer stages is preferred to conserve tissue and avoid sequential testing ...
Alpha Tau Medical (NASDAQ:DRTS) provided investors with a series of clinical, regulatory and financial updates, highlighting ...
The CAPTAIN trial shows faster recovery, fewer complications, and better early function with the minimally invasive therapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results